IL6 and systemic sclerosis: Work in systemic sclerosis, an autoimmune fibrotic pathology affecting skin and internal organs, revealed that IL-6 inhibition leads to a reduction in fibrotic markers such as α-Smooth Muscle Actin expression and a decrease in dermal thickening, suggesting that IL-6 may indeed have pleiotropic effects on the scarring process [42,45].